山东新华制药股份有限公司

投资者关系

信息透明，信任同行

2025-06-30

Overseas Regulatory Announcement-Announcement on Ibuprofen Arginine Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

2025-06-30

海外監管公告-關於獲得精氨酸布洛芬化學原料藥上市申請批准通知書的公告

2025-06-30

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

2025-06-30

海外監管公告-關於獲得《藥品補充申請批准通知書》等相關情況的公告

2025-06-27

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

2025-06-27

海外監管公告-關於獲得《藥品補充申請批准通知書》等相關情況的公告

2025-06-19

Overseas Regulatory Announcement- Announcement on the Completion of Enrollment of the First Patient in China for Phase II Clinical Trials of OAB-14 Dry Suspension

2025-06-19

海外監管公告-關於OAB-14幹混懸劑完成Ⅱ期臨床中國首例患者入組的公告

2025-06-13

Articles of Association

2025-06-13

公司章程